Dassault Systèmes: Q2 well aligned with objectives; Reaffirming 2025 growth outlook Advancing AI for software-defined industries
July 24, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Get the latest news
delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
Belgium 32 800 50 201
France 33 800 943355
Advertisement
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Advertisement
Switzerland 41 43 210 11 32
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit http://www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Advertisement
Contacts
Media:
Ben Petok
[email protected]
Advertisement
Investors:
Alexandra Roy
[email protected]
Advertisement
